Stockreport

NovaBridge Presents Positive Ragistomig Phase 1 Dose Expansion Data at ESMO-IO

NovaBridge Biosciences - American Depositary Shares  (NBP) 
PDF Ragistomig is a 4-1BB X PD-L1 bispecific antibody, designed to treat patients with advanced or metastatic solid tumors, including those who have relapsed or are refracto [Read more]